methyl 4-methoxy-2-nitro-5-(trifluoromethylsulfonyloxy)benzoate | 215659-04-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-methoxy-2-nitro-5-(trifluoromethylsulfonyloxy)benzoate
• CAS: 215659-04-4
• 化学式: C₁₀H₈F₃NO₈S
• 分子量: 359.237
• InChiKey: KQTZZLJPJWENDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.62
• 重原子数：
  23.0
• 可旋转键数：
  5.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  122.04
• 氢给体数：
  0.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  methyl 4-methoxy-2-nitro-5-(trifluoromethylsulfonyloxy)benzoate 在 草酰氯 、 铁粉 、 氯化铵 作用下， 以 甲醇 、 乙醇 、 氯仿 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 6.0h， 生成 4-(4-chloro-7-methoxyquinazolin-6-yl)morpholine
  参考文献：
  名称：

  Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

  摘要：

  Recent reports suggest that an increasing number of patients with lung cancer, especially those with activating mutations of the epidermal growth factor receptor (EGFR), also present with brain metastases and leptomeningeal metastases. These patients have poor prognosis as there are no approved drugs for these indications. Available agents have poor efficacy for these patients even at well above their standard dose. Herein, we report the discovery of (4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl (2R)-2,4-dimethylpiperazine-1-carboxylate 1m (AZD3759), an investigational drug currently in Phase 1 clinical trial, which has excellent central nervous system penetration and which induces profound regression of brain metastases in a mouse model.

  DOI：

  10.1021/acs.jmedchem.5b01073
• 作为产物：
  描述：

  3-羟基-4-甲氧基苯甲酸甲酯 在 吡啶 、 硝酸 作用下， 以 二氯甲烷 、 溶剂黄146 为溶剂， 反应 19.0h， 生成 methyl 4-methoxy-2-nitro-5-(trifluoromethylsulfonyloxy)benzoate
  参考文献：
  名称：

  Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk)

  摘要：

  Continued examination of substituted 6-arylquinazolin-4-amines as Clk4 inhibitors resulted in selective inhibitors of Clk1, Clk4, Dyrk1A and Dyrk1B. Several of the most potent inhibitors were validated as being highly selective within a comprehensive kinome scan. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2011.02.114